Pila Pharma AB (OSTO:PILA) Debt-to-Equity : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pila Pharma AB Debt-to-Equity?

Pila Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Pila Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Pila Pharma AB's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr2.58 Mil. Pila Pharma AB's debt to equity for the quarter that ended in Jun. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pila Pharma AB's Debt-to-Equity or its related term are showing as below:

OSTO:PILA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.15 Max: 1.67
Current: 0.58

During the past 6 years, the highest Debt-to-Equity Ratio of Pila Pharma AB was 1.67. The lowest was 0.01. And the median was 0.15.

OSTO:PILA's Debt-to-Equity is ranked worse than
77.68% of 1044 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:PILA: 0.58

Pila Pharma AB Debt-to-Equity Historical Data

The historical data trend for Pila Pharma AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pila Pharma AB Debt-to-Equity Chart

Pila Pharma AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.15

Pila Pharma AB Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial												-	-	1.67	-	-

Competitive Comparison of Pila Pharma AB's Debt-to-Equity

For the Biotechnology subindustry, Pila Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pila Pharma AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pila Pharma AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pila Pharma AB's Debt-to-Equity falls into.

Pila Pharma AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pila Pharma AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	6.661
	=	0.00

Pila Pharma AB's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	2.575
	=	0.00

Pila Pharma AB (OSTO:PILA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pila Pharma AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pila Pharma AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pila Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pila Pharma AB (OSTO:PILA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

5KC:Germany

Address

Vastergatan 1, Malmo, SWE, 211 21

Website

https://www.pilapharma.com

Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

Pila Pharma AB Headlines

No Headlines